AVITA Medical Inc. (RCEL) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

AVITA Medical Inc. (RCEL) Healthcare & Pipeline Overview

AVITA Medical Inc. is a commercial-stage regenerative tissue company specializing in innovative solutions for burn injuries, trauma, chronic wounds, and dermatological conditions. Their flagship RECELL System enables the creation of Spray-On Skin cells, offering a patient-derived treatment option within the medical device sector.

What Is the Investment Thesis for RCEL?

AVITA Medical presents a focused investment opportunity within the regenerative medicine space, driven by its RECELL System and its potential applications beyond burn care. The company's gross margin of 82.1% indicates strong pricing power and efficient production. Growth catalysts include expansion into new indications like trauma and chronic wounds, as well as geographic expansion. However, the company's negative profit margin of -67.8% highlights the need for improved cost management and increased sales. The high beta of 1.89 suggests significant volatility, reflecting the speculative nature of investing in a growth-stage medical device company. Successful commercialization of new applications and strategic partnerships will be crucial for driving long-term value.

Based on FMP financials and quantitative analysis

RCEL Key Highlights

RECELL System is AVITA Medical's lead product, offering a novel approach to burn treatment using Spray-On Skin cells derived from the patient's own skin.

• Gross margin of 82.1% demonstrates strong profitability on sales, indicating efficient production and pricing strategies.
• Market capitalization of $251M reflects the company's current valuation in the regenerative medicine market.
• Operating in the United States, Australia, and the United Kingdom, AVITA Medical has an established presence in key global markets.
• Research collaborations with the University of Colorado School of Medicine and Houston Methodist Research Institute are exploring new applications for AVITA's technology.

Who Are RCEL's Competitors?

RCEL is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance

What Are RCEL's Key Strengths?

Proprietary RECELL System technology.

• High gross margin (82.1%).
• Established presence in key markets.
• Research collaborations with leading institutions.

What Are RCEL's Weaknesses?

Negative profit margin (-67.8%).

• High beta (1.89) indicating volatility.
• Reliance on a single lead product.
• Limited geographic reach.

What Could Drive RCEL Stock Higher?

RCEL catalyst: Expansion into new indications, such as trauma injuries and chronic wounds, with clinical trial results expected in the next 12-18 months.

• Continued commercialization of the RECELL System in the United States, Australia, and the United Kingdom.
• Potential regulatory approvals for dermatological and aesthetic applications in the next 24 months.
• Strategic partnerships and collaborations to expand market reach and product development.

What Are the Key Risks for RCEL?

Financial-distress signal — its Altman Z-Score of -11.75 sits in the distress zone (elevated bankruptcy risk).

• Inconsistent delivery — missed Wall Street EPS estimates in 6 of the last 8 reported quarters.
• Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
• Competition from established wound care companies with greater resources and market share.
• Regulatory hurdles and delays in obtaining approvals for new products and applications.
• Reimbursement challenges from healthcare providers and insurance companies.
• Product liability claims and litigation related to the use of the RECELL System.

What Are the Growth Opportunities for RCEL?

• Expansion into Trauma Injuries: AVITA Medical has the opportunity to extend the application of its RECELL System beyond burn injuries to address trauma injuries. The market for trauma care is substantial, with a significant need for effective wound healing solutions. By demonstrating the efficacy of RECELL in treating trauma-related wounds, AVITA can tap into a new patient population and drive revenue growth. Clinical trials and regulatory approvals will be necessary to support this expansion, with a potential timeline of 2-3 years for commercialization.
• Penetration of Chronic Wound Market: Chronic wounds, such as diabetic ulcers and pressure ulcers, represent a significant burden on healthcare systems. AVITA Medical can leverage its regenerative tissue technology to develop solutions for chronic wound healing. This market is characterized by a high unmet need and a growing demand for advanced therapies. Successful development and commercialization of products for chronic wounds could significantly expand AVITA's revenue base. This expansion could take 3-5 years, including research, clinical trials, and regulatory approvals.
• Geographic Expansion: AVITA Medical currently operates in the United States, Australia, and the United Kingdom. Expanding into new geographic markets, such as Europe and Asia, represents a significant growth opportunity. These regions have large patient populations and increasing healthcare spending. Entering new markets requires regulatory approvals, establishing distribution networks, and adapting marketing strategies to local conditions. This expansion could be phased over 2-4 years, targeting key markets with favorable regulatory environments and healthcare infrastructure.
• Dermatological and Aesthetic Applications: AVITA Medical is exploring the use of its technology in dermatological and aesthetic applications, including vitiligo. The market for aesthetic treatments is large and growing, driven by increasing consumer demand for cosmetic procedures. By developing products for skin rejuvenation and pigmentation disorders, AVITA can diversify its revenue streams and tap into a new market segment. Clinical studies and regulatory approvals will be necessary to support these applications, with a potential timeline of 2-3 years for commercialization.
• Strategic Partnerships and Collaborations: AVITA Medical can accelerate its growth by forming strategic partnerships and collaborations with other companies in the healthcare industry. These partnerships can provide access to new technologies, markets, and distribution channels. Collaborations with research institutions can also drive innovation and expand the applications of AVITA's technology. Successful partnerships can enhance AVITA's competitive position and drive long-term value creation. Ongoing collaborations with the University of Colorado School of Medicine and Houston Methodist Research Institute exemplify this strategy.

What Are RCEL's Competitive Advantages?

• Patented and proprietary platform technology provides a competitive advantage.
• RECELL System offers a unique approach to burn treatment using Spray-On Skin cells.
• Established presence in the United States, Australia, and the United Kingdom.
• Research collaborations with leading institutions enhance innovation and product development.

What Does RCEL Do?

AVITA Medical Inc., founded in 2000 and based in Valencia, California, is a regenerative tissue company focused on addressing unmet medical needs. Originally incorporated as AVITA Therapeutics, Inc., the company rebranded to AVITA Medical Inc. in December 2020. AVITA's core business revolves around its patented and proprietary platform technology, which harnesses the regenerative properties of a patient's own skin to create treatment solutions. The company's lead product, the RECELL System, is a medical device that allows healthcare professionals to produce a suspension of Spray-On Skin cells from a small sample of the patient's skin. This suspension is then used in the treatment of acute thermal burns in patients eighteen years and older. Beyond burn care, AVITA Medical is exploring applications of its technology in trauma injuries, chronic wounds, and dermatological and aesthetic indications, including vitiligo. The company has established research collaborations with institutions like the University of Colorado School of Medicine and Houston Methodist Research Institute to further explore the potential of its cell suspension delivery system in areas such as genetically corrected cells and molecular reversal of cellular aging. AVITA Medical operates in the United States, Australia, and the United Kingdom, commercializing its regenerative products to address a range of medical needs.

What Products and Services Does RCEL Offer?

• Develops and commercializes regenerative tissue products.
• Offers solutions for burn injuries, trauma injuries, and chronic wounds.
• Provides treatments for dermatological and aesthetic indications, including vitiligo.
• Utilizes a patented platform technology based on the regenerative properties of a patient's own skin.
• Offers the RECELL System, a device for creating Spray-On Skin cells.
• Conducts research collaborations to explore new applications of its technology.
• Operates in the United States, Australia, and the United Kingdom.

How Does RCEL Make Money?

• Develops and manufactures the RECELL System.
• Sells the RECELL System to hospitals and burn centers.
• Generates revenue from the sale of single-use consumables associated with the RECELL System.
• Pursues research collaborations to expand the applications of its technology.

What Industry Does RCEL Operate In?

AVITA Medical operates in the medical device industry, specifically within the regenerative medicine segment. This sector is characterized by rapid innovation and increasing demand for advanced wound care solutions. AVITA Medical's RECELL System competes with traditional skin grafting techniques and other advanced wound care products. The company's ability to differentiate itself through its proprietary technology and clinical outcomes will be critical for success in this competitive landscape.

Who Are RCEL's Key Customers?

• Hospitals and burn centers treating patients with acute thermal burns.
• Physicians and healthcare professionals specializing in wound care.
• Patients seeking advanced treatment options for burn injuries, trauma, and chronic wounds.
• Dermatologists and aesthetic practitioners treating skin conditions and performing cosmetic procedures.

Company Profile

AVITA Medical Inc. operates in the Medical - Devices industry within the Healthcare sector. It is headquartered in Valencia, US. The company is led by CEO Cary G. Vance. RCEL has traded publicly since 2012.

AVITA Medical Inc. Financial Trajectory

AVITA Medical Inc. (RCEL) reported $21.7M in revenue for Q2 2026, reflecting 12.7% growth compared to the prior quarter. The company recorded a net loss of $7.7M, with diluted EPS of $-0.25. Revenue has increased across the last three reported quarters, suggesting sustained momentum for this micro-cap Healthcare company. Across the four most recent quarters, RCEL averaged $-0.36 in diluted EPS.

How AVITA Medical Inc. Is Valued

AVITA Medical Inc. carries a market capitalization of $251M, placing it in the micro-cap category. Relative to its peer group, RCEL's quantitative score of 17/100 is below the peer average of 73/100.

Return on equity for AVITA Medical Inc. stands at 231.9%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -90.2%, showing how much profit it generates from its asset base. Its free cash flow yield is -11.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.41 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -17.3%, the inverse of the P/E and a quick read on earnings relative to price.

AVITA Medical Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -11.75 places it in the distress zone, a signal of elevated financial risk.

AVITA Medical Inc. has missed Wall Street's EPS estimate in 6 of its last 8 reported quarters — a recurring pattern of falling short of estimates. Reported results have landed about 21.6% below estimates on average.

Wall Street analysts project AVITA Medical Inc. revenue of about $82.8M for fiscal 2026, with EPS near $-1.05. The estimate reflects 4 contributing analysts.

RCEL Financials

RCEL Latest News

RCEL Analyst Consensus

RCEL MoonshotScore

RCEL Healthcare Stock FAQ

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources